Mission Bio Raises $70 Million Series C to Accelerate Development of Cancer Therapies with Single-cell Multi-omics

Read the full article in TechCrunch, here.

SOUTH SAN FRANCISCO, Calif. (August 13, 2020) Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced $70 million in its Series C financing led by Novo Growth, the growth equity arm of Novo Holdings. Soleus Capital also joins the round, along with earlier investors Mayfield, Cota, and Agilent, bringing the company’s total funding to more than $120 million. To support Mission Bio’s rapid growth, the funds will scale its single-cell multi-omics technology, the Tapestri® Platform, to expand the company’s reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.

As part of this announcement, Robert Ghenchev, Senior Partner and Head of Novo Growth, has joined Mission Bio’s board of directors. “In Novo Growth, our strategy is to support companies developing cutting edge science that has significant potential to positively impact patients and society. Single-cell analysis has proven highly valuable in cancer research, and we are confident the technology will be used increasingly to unlock key insights into blood cancers, as well as solid tumor indications. We further see a clear opportunity in drug development, where the technology can bring great impact to patients’ lives,” said Ghenchev. “We are impressed with Mission Bio’s innate approach to data integration at the single-cell level and are excited to contribute more than capital by activating our broad life science network to support their mission to greatly impact the success and economics of precision therapy development.”